(Q40035117)

English

Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs

scientific article published on 20 October 2008

Statements

Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit